BlackRock’s Solid Biosciences SLDB Stock Holding History

BlackRock’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.7M	Buy	4,958,354 +88,672	+2%	+$570K	﹤0.01%	2731
2025 Q4	$27.5M	Buy	4,869,682 +144,564	+3%	+$783K	﹤0.01%	2905
2025 Q3	$29.2M	Sell	4,725,118 -194,965	-4%	-$1.14M	﹤0.01%	2853
2025 Q2	$24M	Buy	4,920,083 +2,769,210	+129%	+$9.79M	﹤0.01%	2905
2025 Q1	$7.96M	Buy	2,150,873 +290,269	+16%	+$1.24M	﹤0.01%	3433
2024 Q4	$7.44M	Buy	1,860,604 +258,414	+16%	+$1.42M	﹤0.01%	3562
2024 Q3	$11.2M	Buy	1,602,190 +118,928	+8%	+$965K	﹤0.01%	3343
2024 Q2	$8.41M	Buy	1,483,262 +1,176,196	+383%	+$10.5M	﹤0.01%	3472
2024 Q1	$4.09M	Buy	307,066 +192,968	+169%	+$1.81M	﹤0.01%	3756
2023 Q4	$701K	Sell	114,098 -17,185	-13%	-$54.9K	﹤0.01%	4346
2023 Q3	$331K	Sell	131,283 -6,761	-5%	-$26.2K	﹤0.01%	4537
2023 Q2	$723K	Sell	138,044 -717	-0.5%	-$4.04K	﹤0.01%	4379
2023 Q1	$658K	Sell	138,761 -5,303	-4%	-$31.9K	﹤0.01%	4466
2022 Q4	$775K	Sell	144,064 -45,129	-24%	-$296K	﹤0.01%	4494
2022 Q3	$1.32M	Sell	189,193 -2,049	-1%	-$20.7K	﹤0.01%	4379
2022 Q2	$1.77M	Sell	191,242 -196,909	-51%	-$2.05M	﹤0.01%	4301
2022 Q1	$6.99M	Sell	388,151 -28,730	-7%	-$507K	﹤0.01%	3778
2021 Q4	$10.9M	Buy	416,881 +116,101	+39%	+$3.55M	﹤0.01%	3623
2021 Q3	$10.8M	Buy	300,780 +29,531	+11%	+$1.25M	﹤0.01%	3637
2021 Q2	$14.9M	Buy	271,249 +106,230	+64%	+$7.02M	﹤0.01%	3470
2021 Q1	$13.7M	Buy	165,019 +31,864	+24%	+$3.53M	﹤0.01%	3394
2020 Q4	$15.1M	Sell	133,155 -15,776	-11%	-$998K	﹤0.01%	3153
2020 Q3	$4.53M	Sell	148,931 -5,056	-3%	-$194K	﹤0.01%	3616
2020 Q2	$6.77M	Buy	153,987 +26,154	+20%	+$1.09M	﹤0.01%	3403
2020 Q1	$4.58M	Sell	127,833 -208	-0.2%	-$10.3K	﹤0.01%	3393
2019 Q4	$8.55M	Buy	128,041 +15,276	+14%	+$1.69M	﹤0.01%	3318
2019 Q3	$17.5M	Buy	112,765 +24,175	+27%	+$2.74M	﹤0.01%	2891
2019 Q2	$7.64M	Buy	88,590 +8,701	+11%	+$949K	﹤0.01%	3370
2019 Q1	$11M	Sell	79,889 -1,072	-1%	-$269K	﹤0.01%	3069
2018 Q4	$32.5M	Buy	80,961 +29,078	+56%	+$13.7M	﹤0.01%	2465
2018 Q3	$36.7M	Buy	51,883 +12,154	+31%	+$7.64M	﹤0.01%	2548
2018 Q2	$21.2M	Sell	39,729 -2,895	-7%	-$891K	﹤0.01%	2819
2018 Q1	$4.79M	Buy	+42,624	New	+$14.4M	﹤0.01%	3439

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock's SLDB Position: Q1 2026 in Review

BlackRock increased its Solid Biosciences (SLDB) stake by 1.8% in Q1 2026, buying an estimated $570K and bringing the position to 4,958,354 shares worth $35.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2731.

BlackRock first reported a position in SLDB in Q1 2018 and has held it in 33 quarters since. The position peaked at $36.7M in Q3 2018. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

BlackRock held 4,958,354 shares of Solid Biosciences worth $35.7M as of Q1 2026.
BlackRock bought 88,672 Solid Biosciences shares in Q1 2026, an estimated $570K.
Solid Biosciences made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2731 holding.
BlackRock first reported a position in Solid Biosciences in Q1 2018 and has held it in 33 quarters since.
BlackRock's Solid Biosciences position peaked at $36.7M in Q3 2018.
150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.